Amgen Clinical Trials: 1,056 Led Studies

Archive historyOct 2022 to Jun 2026

155 recorded changes across Amgen trials

Every status move, completion date shift and enrollment change ComplyRx has recorded across 39 of these trials. One is shown below.

Completion date movePrimary completion moved 187 days laterNCT05094336 · recorded 1 Jun 2026

Track to read them

+151 more recorded changes · Track a drug to see every change the night it lands

Track sotorasib

Most active programmes

The drugs appearing most often across Amgen's recently active trials. Comparator arms are excluded.

Sotorasib7 trials
Tarlatamab7 trials
Maridebart Cafraglutide6 trials
Xaluritamig6 trials
Maridebart cafraglutide6 trials
Blinatumomab6 trials

Upcoming readouts

Next primary completion dates among Amgen's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.

Jun 2027A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet …Phase 3
Jul 2027A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Afl…Phase 3
Sept 2027A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevate…Phase 2
Sept 2027MARITIME-OSA-2: Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on…Phase 3
Sept 2027MARITIME-OSA-1: Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Pos…Phase 3
Jan 2028A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G1…Phase 2

Top therapeutic areas

Conditions studied most often across Amgen's recently active trials.

Obesity7 trials
Overweight5 trials
Atopic Dermatitis3 trials
Thyroid Eye Disease3 trials
Cardiovascular Disease3 trials
Extensive Stage Small Cell Lung Cancer3 trials

Amgen trials

The 50 most significant of Amgen's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.

Trial	Phase	Stability	Status	Enrollment	Est. readout
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous DoseNCT07422285Evolocumab Drug Substance A	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	405 est.	24 Jul 2026
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.NCT07545226Evolocumab Drug Substance A (Test)	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	405 est.	3 Sept 2026
Single and Multiple Ascending Dose Study of AMG 513 in Participants With ObesityNCT06585462AMG 513	Phase 1	Locked · track to reveal	OngoingRecruiting	80 est.	1 Oct 2026
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)NCT06593522anvumetostat	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	61 est.	31 Oct 2026
MTAPESTRY 103A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)NCT06360354Anvumetostat	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	120 est.	31 Oct 2026
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).NCT06333951Anvumetostat	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	49 est.	31 Oct 2026
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes MellitusNCT07160257Maridebart cafraglutide	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	56 est.	15 Nov 2026
Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or ObesityNCT07523711COC	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	49 est.	18 Nov 2026
MTAPESTRY 101A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)NCT05094336Anvumetostat	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	329 est.	30 Nov 2026
EucalyptusPharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)NCT06430866ABP 234	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	163 est.	14 Dec 2026
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)NCT06700343Ocrelizumab (US)	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	152 est.	15 Jan 2027
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate CancerNCT06613100Xaluritamig	Phase 1	Locked · track to reveal	OngoingRecruiting	40 est.	22 Jan 2027
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye DiseaseNCT06401044AMG 732	Phase 1	Locked · track to reveal	OngoingRecruiting	88 est.	22 Feb 2027
A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate AsthmaNCT06637371AMG 691	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	21 est.	10 Apr 2027
DeLLphi-308Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)NCT06598306Tarlatamab	Phase 1	Locked · track to reveal	OngoingRecruiting	220 est.	24 Apr 2027
A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland ChinaNCT06588153Prolia®	Phase 4	Locked · track to reveal	OngoingActive, not recruiting	102 est.	27 Apr 2027
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis ImperfectaNCT05972551Romosozumab	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	111 est.	4 May 2027
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)NCT05920356Sotorasib	Phase 3	Locked · track to reveal	OngoingRecruiting	750 est.	30 Jun 2027
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.NCT06321601Avacopan	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	19 est.	18 Jul 2027
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular DegenerationNCT07614776ABP 938 8 mg	Phase 3	Locked · track to reveal	OngoingRecruiting	304 est.	31 Jul 2027
MARITIME-OSA-2Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) TherapyNCT07226765Maridebart cafraglutide	Phase 3	Locked · track to reveal	OngoingRecruiting	250 est.	29 Sept 2027
MARITIME-OSA-1Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyNCT07225686Maridebart cafraglutide	Phase 3	Locked · track to reveal	OngoingRecruiting	250 est.	29 Sept 2027
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or OverweightNCT07441252Maridebart cafraglutide	Phase 2	Locked · track to reveal	OngoingRecruiting	180 est.	29 Sept 2027
A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes MellitusNCT07590193AMG 127	Phase 1	Locked · track to reveal	OngoingRecruiting	162 est.	2 Oct 2027
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALLNCT04521231Blinatumomab	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	181 est.	24 Nov 2027
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)NCT07684144Maridebart Cafraglutide	Phase 3	Not yet scored	OngoingNot yet recruiting	950 est.	26 Dec 2027
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)NCT07684235Maridebart cafraglutide	Phase 3	Not yet scored	OngoingNot yet recruiting	3,200 est.	26 Dec 2027
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C MutationNCT07172919Sotorasib	Phase 2	Locked · track to reveal	OngoingRecruiting	14 est.	2 Jan 2028
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)NCT07575399Maridebart Cafraglutide	Phase 3	Locked · track to reveal	OngoingRecruiting	300 est.	3 Jan 2028
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung CancerNCT06311721ABP 234	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	315 est.	10 Jan 2028
HAZEL 401An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye DiseaseNCT07438405AMG 732	Phase 2	Locked · track to reveal	OngoingRecruiting	30 est.	29 Jan 2028
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate CancerNCT07493512Xaluritamig	Phase 1	Locked · track to reveal	OngoingRecruiting	40 est.	30 Jan 2028
DeLLphi-311A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)NCT07037758Tarlatamab	Phase 1	Locked · track to reveal	OngoingRecruiting	380 est.	18 Mar 2028
PEAPODApremilast Pediatric Study in Children With Active Juvenile Psoriatic ArthritisNCT04804553Apremilast	Phase 3	Locked · track to reveal	OngoingRecruiting	60 est.	21 Mar 2028
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate CancerNCT07140900Xaluritamig	Phase 1	Locked · track to reveal	OngoingRecruiting	60 est.	27 Mar 2028
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid TumorsNCT07094113AMG 410	Phase 1	Locked · track to reveal	OngoingRecruiting	434 est.	18 Apr 2028
Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis ImperfectaNCT07366086Vitamin D	Phase 3	Locked · track to reveal	OngoingRecruiting	71 est.	19 Apr 2028
DeLLphi-313Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)NCT07531095ZL-1310	Phase 1	Locked · track to reveal	OngoingRecruiting	160 est.	21 May 2028
OCEAN(a)-CCTAOlpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography TrialNCT07293260Olpasiran	Phase 3	Locked · track to reveal	OngoingRecruiting	406 est.	15 Jun 2028
A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled GoutNCT07388498Pegloticase	Phase 3	Locked · track to reveal	OngoingRecruiting	270 est.	18 Jun 2028
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid TumorsNCT07403721AMG 436	Phase 1	Locked · track to reveal	OngoingRecruiting	464 est.	28 Jun 2028
MARITIME-CVEvaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433Maridebart Cafraglutide	Phase 3	Locked · track to reveal	OngoingRecruiting	12,800 est.	30 Jun 2028
MARITIME-HFMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459Maridebart cafraglutide	Phase 3	Locked · track to reveal	OngoingRecruiting	5,056 est.	30 Jun 2028
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune DiseasesNCT06570798Inebilizumab	Phase 2	Locked · track to reveal	OngoingRecruiting	220 est.	21 Jul 2028
CodeBreaK 301Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C MutationNCT06252649FOLFIRI Regimen	Phase 3	Locked · track to reveal	OngoingRecruiting	450 est.	25 Sept 2028
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic LeukemiaNCT07134088Blinatumomab	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	104 est.	5 Dec 2028
A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular DiseaseNCT06295679	—	Not yet scored	OngoingRecruiting	7,000 est.	19 Dec 2028
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)NCT06691984Xaluritamig	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	707 est.	2 Jan 2029
DeLLphi-312A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)NCT07005128Tarlatamab	Phase 3	Locked · track to reveal	OngoingRecruiting	330 est.	4 Jan 2029
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic LeukemiaNCT04994717Blinatumomab	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	303 est.	7 Sept 2029

View all trials1,056

MTAPESTRY 103: A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

Phase 1Active, not recruitingNCT06360354 ↗

Primary completion: Oct 2026; estimated
Enrollment: 120; estimated
Start: May 2024; Amgen

Conditions

Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

Interventions

Anvumetostat
Gemcitabine
Nab-paclitaxel
Modified FOLFIRINOX
RMC-6236

Brief summary

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal,…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Sept 2025

Enrollment change · 2

Completion date move · 1

Track Amgen drugs to see every change the night it lands.

Track sotorasib

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

Phase 1Active, not recruitingNCT06333951 ↗

Primary completion: Oct 2026; estimated
Enrollment: 49; estimated
Start: Sept 2024; Amgen

Conditions

Thoracic Tumors
Non-small Cell Lung Cancer

Interventions

Anvumetostat
Carboplatin
Paclitaxel
Pembrolizumab
Pemetrexed
Sotorasib

Brief summary

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Jun 2026

Completion date move · 3

Status change · 2

Enrollment change · 1

Track Amgen drugs to see every change the night it lands.

Track sotorasib

MTAPESTRY 101: A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

Phase 1Active, not recruitingNCT05094336 ↗

Primary completion: Nov 2026; estimated
Enrollment: 329; estimated
Start: Feb 2022; Amgen

Conditions

Advanced MTAP-null Solid Tumors

Interventions

Anvumetostat
Docetaxel
Comparator Anvumetostat Test Tablet

Brief summary

The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of Anvumetostat alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine…

Full record on ClinicalTrials.gov ↗

Change timeline

16 recorded · latest 1 Jun 2026

Completion date move · 12

Enrollment change · 3

Status change · 1

Track Amgen drugs to see every change the night it lands.

Track sotorasib

Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

Phase 3Active, not recruitingNCT05972551 ↗

Primary completion: May 2027; estimated
Enrollment: 111; estimated
Start: Apr 2024; Amgen

Conditions

Osteogenesis Imperfecta

Interventions

Romosozumab
Bisphosphonate

Brief summary

The primary objective of this study is to evaluate the effect of romosozumab treatment for 12-months compared with bisphosphonate(s) on the number of clinical fractures at 12-months; the number of any fractures at 12-months and change in lumbar spine bone mineral density (BMD) Z-score at 6-months.

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Jun 2026

Completion date move · 3

Status change · 2

Enrollment change · 1

Track Amgen drugs to see every change the night it lands.

Track sotorasib

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Phase 3RecruitingNCT05920356 ↗

Primary completion: Jun 2027; estimated
Enrollment: 750; estimated
Start: Nov 2023; Amgen

Conditions

Non-Small Cell Lung Cancer (NSCLC)

Interventions

Sotorasib
Pembrolizumab

Brief summary

The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 May 2026

Completion date move · 3

Status change · 1

Track Amgen drugs to see every change the night it lands.

Track sotorasib

MARITIME-OSA-1: Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Phase 3RecruitingNCT07225686 ↗

Primary completion: Sept 2027; estimated
Enrollment: 250; estimated
Start: Dec 2025; Amgen

Conditions

Obesity
Obstructive Sleep Apnea

Interventions

Maridebart cafraglutide
Placebo

Brief summary

This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or obesity.

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Feb 2026

Status change · 1

Track Amgen drugs to see every change the night it lands.

Track sotorasib

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

Phase 2RecruitingNCT07441252 ↗

Primary completion: Sept 2027; estimated
Enrollment: 180; estimated
Start: Mar 2026; Amgen

Conditions

Overweight or Obesity and Elevated Liver Fat

Interventions

Maridebart cafraglutide
Placebo

Brief summary

The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver fat content, when administered in conjunction with reduced-calorie diet and increased…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Apr 2026

Status change · 1

Track Amgen drugs to see every change the night it lands.

Track sotorasib

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Phase 1Active, not recruitingNCT04521231 ↗

Primary completion: Nov 2027; estimated
Enrollment: 181; estimated
Start: Jan 2021; Amgen

Conditions

B Cell Precursor Acute Lymphoblastic Leukemia

Interventions

Blinatumomab

Brief summary

The Phase I part of the study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL), to determine the maximum tolerated dose (MTD), and recommended phase 2 dose(s) (RP2D) of SC…

Full record on ClinicalTrials.gov ↗

Change timeline

19 recorded · latest 1 Jun 2026

Completion date move · 11

Enrollment change · 5

Status change · 3

Track Amgen drugs to see every change the night it lands.

Track sotorasib

DeLLphi-311: A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

Phase 1RecruitingNCT07037758 ↗

Primary completion: Mar 2028; estimated
Enrollment: 380; estimated
Start: Sept 2025; Amgen

Conditions

Extensive Stage Small Cell Lung Cancer

Interventions

Tarlatamab
AB248

Brief summary

The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to determine the recommended dose for expansion and/or maximum tolerated combination dose (MTCD) of AB248 in combination…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Nov 2025

Status change · 1

Track Amgen drugs to see every change the night it lands.

Track sotorasib

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

Phase 1RecruitingNCT07094113 ↗

Primary completion: Apr 2028; estimated
Enrollment: 434; estimated
Start: Jul 2025; Amgen

Conditions

KRAS Altered Advanced or Metastatic Solid Tumors

Interventions

AMG 410
Pembrolizumab
Panitumumab

Brief summary

The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combination with other agents in participants with advanced or metastatic solid tumors harboring KRAS alterations. This is a…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Mar 2026

Completion date move · 2

Status change · 1

Track Amgen drugs to see every change the night it lands.

Track sotorasib

A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout

Phase 3RecruitingNCT07388498 ↗

Primary completion: Jun 2028; estimated
Enrollment: 270; estimated
Start: Feb 2026; Amgen

Conditions

Uncontrolled Gout

Interventions

Pegloticase
Methotrexate

Brief summary

The primary objective of this trial is to evaluate the effect of pegloticase 18 mg subcutaneously (SC) every two weeks with methotrexate (MTX) versus pegloticase 8 mg intravenously (IV) every two weeks with MTX on the response rate during Month 6, as measured by the sustained normalization of serum uric acid (sUA) to…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

Phase 1RecruitingNCT07403721 ↗

Primary completion: Jun 2028; estimated
Enrollment: 464; estimated
Start: Apr 2026; Amgen

Conditions

Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)

Interventions

AMG 436

Brief summary

The primary objectives of this trial are to evaluate the safety profile of AMG 436 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for AMG 436 as monotherapy and in combination with other anti-cancer therapies in participants with MSI-H/dMMR solid tumors.

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Apr 2026

Completion date move · 1

Status change · 1

Track Amgen drugs to see every change the night it lands.

Track sotorasib

MARITIME-CV: Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Phase 3RecruitingNCT07037433 ↗

Primary completion: Jun 2028; estimated
Enrollment: 12,800; estimated
Start: Jul 2025; Amgen

Conditions

Atherosclerotic Cardiovascular Disease
Overweight
Obesity

Interventions

Maridebart Cafraglutide
Placebo

Brief summary

The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Aug 2025

Status change · 1

Track Amgen drugs to see every change the night it lands.

Track sotorasib

MARITIME-HF: Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Phase 3RecruitingNCT07037459 ↗

Primary completion: Jun 2028; estimated
Enrollment: 5,056; estimated
Start: Jun 2025; Amgen

Conditions

Heart Failure With Preserved Ejection Fraction
Heart Failure With Mildly Reduced Ejection Fraction
Obesity

Interventions

Maridebart cafraglutide
Placebo

Brief summary

This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Aug 2025

Status change · 1

Track Amgen drugs to see every change the night it lands.

Track sotorasib

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

Phase 2RecruitingNCT06570798 ↗

Primary completion: Jul 2028; estimated
Enrollment: 220; estimated
Start: Jul 2025; Amgen

Conditions

Systemic Lupus Erythematosus
Active Refractory Rheumatoid Arthritis

Interventions

Inebilizumab
Blinatumomab

Brief summary

The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE…

Full record on ClinicalTrials.gov ↗

Change timeline

11 recorded · latest 1 Jun 2026

Completion date move · 6

Enrollment change · 4

Status change · 1

Track Amgen drugs to see every change the night it lands.

Track sotorasib

CodeBreaK 301: Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Phase 3RecruitingNCT06252649 ↗

Primary completion: Sept 2028; estimated
Enrollment: 450; estimated
Start: Jul 2024; Amgen

Conditions

Metastatic Colorectal Cancer

Interventions

FOLFIRI Regimen
Sotorasib
Panitumumab
Bevacizumab-awwb

Brief summary

The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Apr 2025

Completion date move · 3

Status change · 1

Track Amgen drugs to see every change the night it lands.

Track sotorasib

A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease

–RecruitingNCT06295679 ↗

Primary completion: Dec 2028; estimated
Enrollment: 7,000; estimated
Start: Dec 2022; Amgen

Conditions

Major Cardiovascular Event
Established Atherosclerotic Cardiovascular Disease

Brief summary

The primary objective of the study is to evaluate real-world effectiveness of treatment with Repatha® in combination with SOC, compared with SOC alone, on the risk for cardiovascular (CV) death, myocardial infarction (MI), stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Phase 3Active, not recruitingNCT06691984 ↗

Primary completion: Jan 2029; estimated
Enrollment: 707; estimated
Start: Dec 2024; Amgen

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

Xaluritamig
Abiraterone
Enzalutamide
Cabazitaxel

Brief summary

The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy \[ARDT\]).

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Jun 2026

Status change · 1

Enrollment change · 1

Completion date move · 1

Track Amgen drugs to see every change the night it lands.

Track sotorasib

DeLLphi-312: A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

Phase 3RecruitingNCT07005128 ↗

Primary completion: Jan 2029; estimated
Enrollment: 330; estimated
Start: Aug 2025; Amgen

Conditions

Small-cell Lung Cancer
Extensive Stage Small-cell Lung Cancer

Interventions

Tarlatamab
Durvalumab
Carboplatin
Etoposide

Brief summary

The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Sept 2025

Status change · 1

Track Amgen drugs to see every change the night it lands.

Track sotorasib

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

Phase 3Active, not recruitingNCT04994717 ↗

Primary completion: Sept 2029; estimated
Enrollment: 303; estimated
Start: Nov 2021; Amgen

Conditions

Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Interventions

Blinatumomab
Low-intensity chemotherapy regimen
SOC chemotherapy regimen

Brief summary

The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of participants receiving blinatumomab alternating with low-intensity…

Full record on ClinicalTrials.gov ↗

Change timeline

10 recorded · latest 1 Jun 2026

Completion date move · 8

Status change · 1

Enrollment change · 1

Track Amgen drugs to see every change the night it lands.

Track sotorasib